drugset / Trial / NCT06778395

Therapeutic Effect of Vonoprazan Versus Dexlansoprazole in Treatment of Gastroesophageal Reflux Disease

NCT06778395

RandomizedParallel-groupOpen-labelTreatment

Summary

Gastroenterologists are often hesitated about whether to use the well known PPI in treatment of GERD or the usage of new H/K ATPase inhibitors so its highly needed to test the benefit of each class in Egyptian population to help doctors in decision making

Timeline

Start
2024-10-01
Primary completion
2024-12-31
Completion
2024-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexlansoprazole Other / unclassified 60 mg
Comparator Vonoprazan Other / unclassified 20 mg